Anti-Infectives · LP-027
Azithromycin Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-027Anti-Infectives
- Generic identity
- AzithromycinTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-027
- Generic identity
- Azithromycin
- Presentation
- Tablet
- Catalogue strength
- 250 mg; 500 mg
- Catalogue pack
- Blister 3 or 6 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: azithromycin.
- Dosage form: tablet.
- Proposed strengths: 250 mg and 500 mg.
- General proposed pack options: blister 3 tablets or blister 6 tablets.
Layer 02 · Unresolved product-specific fields
- Strength-to-tablet-count/SKU mapping.
- Tablet coating/score and divisibility.
- Exact azithromycin salt/basis and excipients.
- Approved indication/duration, storage, shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 250 mg | Tablet | — | Blister 3 or 6 tablets; strength-to-count mapping not supplied | Do not infer both pack counts exist for this strength. |
| B | 500 mg | Tablet | — | Blister 3 or 6 tablets; strength-to-count mapping not supplied | Do not infer both pack counts exist for this strength. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Azithromycin is a macrolide antibiotic used for selected infections caused by susceptible bacteria. Tablet and oral suspension presentations support different administration needs, but neither makes the medicine appropriate for an undiagnosed respiratory illness. Antibiotic resistance and patient safety are important limits on use. This ingredient-level educational profile does not establish a Luang Pharma indication, registration, effectiveness claim or pediatric authorization.
Clinical context and therapeutic role
The clinical indication should be supported by assessment of the likely organism, local resistance and the role of alternative antibiotics. Respiratory, skin and other infections require condition-specific decisions rather than a generic broad-spectrum claim. Cardiac history and concurrent medicines are particularly relevant. When a liquid is selected for a child or a person with swallowing difficulty, the prescribed concentration, preparation instructions and measuring device must be confirmed.
Selected safety context
Azithromycin can affect cardiac repolarization and cause serious rhythm disturbances in susceptible patients, particularly with low potassium, a prolonged QT interval or interacting medicines. Liver injury, severe allergy and significant antibiotic-associated diarrhoea are additional concerns. Nausea, abdominal discomfort and diarrhoea may occur. Fainting, new palpitations, jaundice, breathing difficulty or blistering rash need urgent assessment. A clinician should reassess persistent symptoms rather than automatically repeat or extend antibiotic exposure.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification/formula for each strength.
Approved label/leaflet identifying administration and any score/divisibility instructions.
Strength-to-count/SKU matrix and artwork.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: AzithromycinArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| NHS: About azithromycinArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 30 January 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-027.
Professional enquiries
Request product-specific evidence for LP-027.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.